SK285454B6 - Use of biochemical substances in a composition for the prevention and treatment of health conditions caused by constrictions of smooth muscle cells in organs of the human body - Google Patents
Use of biochemical substances in a composition for the prevention and treatment of health conditions caused by constrictions of smooth muscle cells in organs of the human body Download PDFInfo
- Publication number
- SK285454B6 SK285454B6 SK823-2001A SK8232001A SK285454B6 SK 285454 B6 SK285454 B6 SK 285454B6 SK 8232001 A SK8232001 A SK 8232001A SK 285454 B6 SK285454 B6 SK 285454B6
- Authority
- SK
- Slovakia
- Prior art keywords
- glycinate
- magnesium
- arginine
- alpha
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 239000000126 substance Substances 0.000 title abstract description 5
- 210000000329 smooth muscle myocyte Anatomy 0.000 title description 13
- 210000000056 organ Anatomy 0.000 title description 7
- 230000002265 prevention Effects 0.000 title description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 31
- 208000006673 asthma Diseases 0.000 claims abstract description 18
- 208000009205 Tinnitus Diseases 0.000 claims abstract description 13
- 231100000886 tinnitus Toxicity 0.000 claims abstract description 13
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 12
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 12
- 239000004475 Arginine Substances 0.000 claims abstract description 11
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 11
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000011777 magnesium Substances 0.000 claims abstract description 11
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 11
- 208000005392 Spasm Diseases 0.000 claims abstract description 10
- -1 ascorbate compound Chemical class 0.000 claims abstract description 8
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 8
- 208000010412 Glaucoma Diseases 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 210000003708 urethra Anatomy 0.000 claims abstract description 6
- 206010000087 Abdominal pain upper Diseases 0.000 claims abstract description 5
- 208000000509 infertility Diseases 0.000 claims abstract description 5
- 230000036512 infertility Effects 0.000 claims abstract description 5
- 231100000535 infertility Toxicity 0.000 claims abstract description 5
- 208000031361 Hiccup Diseases 0.000 claims abstract description 4
- 229940072107 ascorbate Drugs 0.000 claims abstract description 4
- 150000001483 arginine derivatives Chemical class 0.000 claims abstract 2
- 159000000003 magnesium salts Chemical class 0.000 claims abstract 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 claims description 10
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 10
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 claims description 10
- 239000013522 chelant Substances 0.000 claims description 10
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- 235000001055 magnesium Nutrition 0.000 claims description 10
- 229940091250 magnesium supplement Drugs 0.000 claims description 10
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 10
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 claims description 10
- 235000009697 arginine Nutrition 0.000 claims description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 8
- 229930064664 L-arginine Natural products 0.000 claims description 8
- 235000014852 L-arginine Nutrition 0.000 claims description 8
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 7
- 229960003495 thiamine Drugs 0.000 claims description 7
- 235000019157 thiamine Nutrition 0.000 claims description 7
- 239000011721 thiamine Substances 0.000 claims description 7
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 7
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 claims description 5
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 5
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 5
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 5
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 claims description 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 5
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 claims description 5
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 5
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 5
- 229930182821 L-proline Natural products 0.000 claims description 5
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 5
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 5
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 claims description 5
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 5
- 235000003903 alpha-carotene Nutrition 0.000 claims description 5
- 239000011795 alpha-carotene Substances 0.000 claims description 5
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 claims description 5
- 235000013734 beta-carotene Nutrition 0.000 claims description 5
- 239000011648 beta-carotene Substances 0.000 claims description 5
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 5
- 229960002747 betacarotene Drugs 0.000 claims description 5
- 210000000013 bile duct Anatomy 0.000 claims description 5
- 229960002685 biotin Drugs 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- 235000010376 calcium ascorbate Nutrition 0.000 claims description 5
- 229940047036 calcium ascorbate Drugs 0.000 claims description 5
- 239000011692 calcium ascorbate Substances 0.000 claims description 5
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 5
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 claims description 5
- OFNJDDJDXNMTHZ-UHFFFAOYSA-L calcium;2-aminoacetate Chemical compound [Ca+2].NCC([O-])=O.NCC([O-])=O OFNJDDJDXNMTHZ-UHFFFAOYSA-L 0.000 claims description 5
- 235000021466 carotenoid Nutrition 0.000 claims description 5
- 150000001747 carotenoids Chemical class 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 235000012721 chromium Nutrition 0.000 claims description 5
- 229910052804 chromium Inorganic materials 0.000 claims description 5
- 239000011651 chromium Substances 0.000 claims description 5
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 5
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 5
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 5
- VVYPIVJZLVJPGU-UHFFFAOYSA-L copper;2-aminoacetate Chemical compound [Cu+2].NCC([O-])=O.NCC([O-])=O VVYPIVJZLVJPGU-UHFFFAOYSA-L 0.000 claims description 5
- 229960002104 cyanocobalamin Drugs 0.000 claims description 5
- 235000000639 cyanocobalamin Nutrition 0.000 claims description 5
- 239000011666 cyanocobalamin Substances 0.000 claims description 5
- 235000010389 delta-tocopherol Nutrition 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 235000012680 lutein Nutrition 0.000 claims description 5
- 239000001656 lutein Substances 0.000 claims description 5
- 229960005375 lutein Drugs 0.000 claims description 5
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 5
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 5
- 229940074358 magnesium ascorbate Drugs 0.000 claims description 5
- 235000002538 magnesium citrate Nutrition 0.000 claims description 5
- 239000004337 magnesium citrate Substances 0.000 claims description 5
- 229960005336 magnesium citrate Drugs 0.000 claims description 5
- 229940004916 magnesium glycinate Drugs 0.000 claims description 5
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 claims description 5
- AACACXATQSKRQG-UHFFFAOYSA-L magnesium;2-aminoacetate Chemical compound [Mg+2].NCC([O-])=O.NCC([O-])=O AACACXATQSKRQG-UHFFFAOYSA-L 0.000 claims description 5
- 229910052748 manganese Inorganic materials 0.000 claims description 5
- 239000011572 manganese Substances 0.000 claims description 5
- 229910052750 molybdenum Inorganic materials 0.000 claims description 5
- 239000011733 molybdenum Substances 0.000 claims description 5
- 229960003966 nicotinamide Drugs 0.000 claims description 5
- 235000005152 nicotinamide Nutrition 0.000 claims description 5
- 239000011570 nicotinamide Substances 0.000 claims description 5
- 229960003512 nicotinic acid Drugs 0.000 claims description 5
- 235000001968 nicotinic acid Nutrition 0.000 claims description 5
- 239000011664 nicotinic acid Substances 0.000 claims description 5
- 229960002429 proline Drugs 0.000 claims description 5
- 235000008160 pyridoxine Nutrition 0.000 claims description 5
- 239000011677 pyridoxine Substances 0.000 claims description 5
- 239000002151 riboflavin Substances 0.000 claims description 5
- 235000019192 riboflavin Nutrition 0.000 claims description 5
- 229960002477 riboflavin Drugs 0.000 claims description 5
- 229960002718 selenomethionine Drugs 0.000 claims description 5
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 5
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 5
- 229940011671 vitamin b6 Drugs 0.000 claims description 5
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 5
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 5
- 239000002446 δ-tocopherol Substances 0.000 claims description 5
- 241000207199 Citrus Species 0.000 claims description 4
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims description 4
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 4
- 239000001354 calcium citrate Substances 0.000 claims description 4
- 239000001506 calcium phosphate Substances 0.000 claims description 4
- 235000020971 citrus fruits Nutrition 0.000 claims description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 claims description 4
- 229940038472 dicalcium phosphate Drugs 0.000 claims description 4
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims description 4
- 229960000367 inositol Drugs 0.000 claims description 4
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 4
- 235000007686 potassium Nutrition 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 4
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims description 4
- 229960000984 tocofersolan Drugs 0.000 claims description 4
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 4
- 235000005282 vitamin D3 Nutrition 0.000 claims description 4
- 239000011647 vitamin D3 Substances 0.000 claims description 4
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 4
- 229940021056 vitamin d3 Drugs 0.000 claims description 4
- 239000002076 α-tocopherol Substances 0.000 claims description 4
- 235000004835 α-tocopherol Nutrition 0.000 claims description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 3
- 239000004212 Cryptoxanthin Substances 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
- 235000002360 beta-cryptoxanthin Nutrition 0.000 claims description 3
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 claims description 3
- 229960004256 calcium citrate Drugs 0.000 claims description 3
- 235000019244 cryptoxanthin Nutrition 0.000 claims description 3
- 229960003975 potassium Drugs 0.000 claims description 3
- 229940071566 zinc glycinate Drugs 0.000 claims description 3
- UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical compound [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 claims description 3
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims description 2
- 229920002770 condensed tannin Polymers 0.000 claims description 2
- 229960002433 cysteine Drugs 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 235000018192 pine bark supplement Nutrition 0.000 claims description 2
- 229940106796 pycnogenol Drugs 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229940014662 pantothenate Drugs 0.000 claims 2
- 239000011713 pantothenic acid Substances 0.000 claims 2
- 235000019161 pantothenic acid Nutrition 0.000 claims 2
- APYZGXYHYSFUDF-ZBRNBAAYSA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;(2r)-2-amino-3-sulfanylpropanoic acid Chemical compound SC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCCNC(N)=N APYZGXYHYSFUDF-ZBRNBAAYSA-N 0.000 claims 1
- 150000000994 L-ascorbates Chemical class 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 235000010930 zeaxanthin Nutrition 0.000 claims 1
- 239000001775 zeaxanthin Substances 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 abstract description 2
- 210000000626 ureter Anatomy 0.000 abstract description 2
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002681 magnesium compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000005802 health problem Effects 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 8
- 208000016354 hearing loss disease Diseases 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 210000003123 bronchiole Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 208000011623 Obstructive Lung disease Diseases 0.000 description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 description 2
- 230000007248 cellular mechanism Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010051958 Ureteral spasm Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000012076 audiometry Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 229940070404 citrus bioflavonoids Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000004325 uterine smooth muscle cell Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Oblasť technikyTechnical field
Predkladaný vynález sa týka prevencie a liečby zdravotných ťažkosti spôsobených konstrikciou buniek hladkého svalstva v orgánoch ľudského tela, ako tinnitus, astma, glaukóm, neplodnosť, spazmus močovodov a močovej rúry, singultácia, žalúdočné kŕče alebo spazmus žlčovodov.The present invention relates to the prevention and treatment of medical conditions caused by the constriction of smooth muscle cells in human body organs such as tinnitus, asthma, glaucoma, infertility, urethral and urethra spasm, singultation, gastric spasms or bile duct spasm.
Doterajší stav technikyBACKGROUND OF THE INVENTION
Príčina mnohých ochorení ostáva stále neznáma. Medzi takéto ochorenia s neznámym pôvodom patria mnohé rozšírené ochorenia, ako astma, glaukóm a tinnitus. Na celom svete trpia takýmito zdravotnými ťažkosťami stovky miliónov ľudí a ekonomická ujma spoločnosti, ktorá nie je schopná tieto zdravotné ťažkosti efektívne liečiť, je nemerateľná.The cause of many diseases remains unknown. Such diseases of unknown origin include many widespread diseases such as asthma, glaucoma and tinnitus. Worldwide, hundreds of millions of people suffer from such health problems, and the economic detriment of a society that is unable to treat these health problems effectively is immeasurable.
Niekoľko miliónov ľudí na celom svete trpí bronchiálnou astmou (astmou). V neskoršom štádiu je astma vyčerpávajúce ochorenie vedúce k pracovnej neschopnosti a sociálnej izolácii. Príčina tejto choroby ostáva stále neznáma napriek tomu, že sa implikovali alergény, genetické dispozície a psychologické faktory. Spoločným patomechanizmom tohto ochorenia je obštrukcia ventilačných kanálov v pľúcach (bronchiol) a prechodov k alveolám, kde prebieha okysličovanie. Napriek tomu je však bunkový mechanizmus, ktorý spúšťa túto obštrukciu, následne spôsobujúcu astmu, neznámy.Several million people worldwide suffer from bronchial asthma (asthma). At a later stage, asthma is an exhausting disease leading to incapacity for work and social isolation. The cause of this disease remains unknown, despite allergies, genetic predispositions and psychological factors being implicated. The common pathomechanism of this disease is obstruction of the ventilation ducts in the lungs (bronchiol) and passages to the alveoli where oxygenation takes place. However, the cellular mechanism that triggers this obstruction, subsequently causing asthma, is unknown.
Tinnitus je druh poškodenia sluchu, ktoré sa vo väčšine prípadov objavuje náhle a bez varovných signálov. Na svete je viac než milión pacientov trpiacich na tinnitus a príbuzné poškodenia sluchu. Pôvod a patogenéza tohto ochorenia nie sú známe a momentálne neexistuje žiadna efektívna terapia, ktorá by zlepšila sluch pacientov postihnutých tinnitusom. Mnohí z týchto pacientov následne niekoľko rokov alebo dekád trpia poškodeným sluchom s následnou zhoršenou pracovnou schopnosťou a zhoršeným sociálnym životom.Tinnitus is a type of hearing impairment that in most cases occurs suddenly and without warning signals. There are more than a million patients suffering from tinnitus and related hearing impairment in the world. The origin and pathogenesis of this disease are unknown, and there is currently no effective therapy to improve the hearing of patients suffering from tinnitus. Many of these patients subsequently suffer from hearing impairment for several years or decades, with consequent impaired working ability and impaired social life.
Predpokladá sa, že niekoľko zdanlivo rôznych zdravotných ťažkostí, vyskytujúcich sa v rôznych orgánoch, je spôsobených biochemickou disfunkciou toho istého druhu buniek, nazývaných bunky hladkého svalstva. Tento druh svalových buniek nie je riadený vedomím, na rozdiel od napr. svalov rúk alebo nôh. Správna funkcia buniek hladkého svalstva môže byť preto kľúčom k odstráneniu zdravotných problémov vo všetkých orgánoch, kde bunky hladkého svalstva majú kritickú úlohu.Several seemingly different health problems occurring in different organs are thought to be caused by biochemical dysfunction of the same kind of cells, called smooth muscle cells. This type of muscle cell is not controlled by consciousness, unlike e.g. muscles of the hands or feet. Proper functioning of smooth muscle cells can therefore be the key to eliminating health problems in all organs where smooth muscle cells play a critical role.
Predpokladá sa, že v prípade astmy by sa mohol zistiť jej hlavný bunkový mechanizmus. Steny bronchiol a alveolárnych kanálikov sú tvorené vrstvou buniek hladkého svalstva. Ak by sa tieto bunky stiahli - bez ohľadu na spustenie - priemer týchto pľúcnych kanálikov by sa zmenšoval, čo by viedlo k zníženiu ventilácie a okysličovania. U pacientov s astmou a/alebo obštruktívnymi pľúcnymi ochoreniami by sa teda prejavili typické symptómy.It is believed that in the case of asthma, its major cellular mechanism could be ascertained. The walls of bronchioles and alveolar ducts are formed by a layer of smooth muscle cells. If these cells contracted - irrespective of triggering - the diameter of these lung canals would decrease, leading to reduced ventilation and oxygenation. Thus, patients with asthma and / or obstructive pulmonary diseases would experience typical symptoms.
V prípade tinnitusu a poškodenia sluchu sa predpokladá, že oslabenie sluchu je spôsobené spazmom buniek hladkého svalstva, ktoré tvoria výstelku krvných ciev zodpovedných za prísun krvi do vnútorného ucha a k nervovým bunkám sprostredkujúcim akustické signály. Ďalej sa predpokladalo, že spazmus týchto svalových buniek v ušných kapilárach je spôsobený nedostatkom koenzýmov a iných bioenergetických molekúl nevyhnutných na optimálnu metabolickú funkciu týchto buniek.In the case of tinnitus and hearing impairment, hearing loss is believed to be caused by the spasm of smooth muscle cells that form the lining of the blood vessels responsible for the blood supply to the inner ear and to the nerve cells mediating acoustic signals. Furthermore, the spasm of these muscle cells in the ear capillaries was believed to be due to a lack of coenzymes and other bioenergy molecules necessary for optimal metabolic function of these cells.
Vo vedeckej literatúre sa nenašiel žiaden skorší opis tohto konceptu.There was no earlier description of this concept in the scientific literature.
Nedávno sa dosiahol pokrok v pochopení metabolizmu buniek a úlohy niektorých biochemických látok pri udržiavaní ich správnej funkcie. Následne by bola oprava dysfunkcie metabolizmu buniek hladkého svalstva kľúčom k prevencii a liečbe niektorých zdravotných problémov v rôznych telesných orgánoch.Recently, progress has been made in understanding cell metabolism and the role of some biochemical agents in maintaining their proper function. Consequently, repairing dysfunction of smooth muscle cell metabolism would be the key to preventing and treating some health problems in various body organs.
Patentový dokument GB 2268871 opisuje potravinové doplnky obsahujúce proteín alebo peptid, vitamín aminokyselinu a horčík. Tento potravinový doplnok sa používa na posilnenie činnosti srdca a cirkulácie, čo nie je predmetom predloženého vynálezu.GB 2268871 discloses dietary supplements comprising protein or peptide, vitamin amino acid and magnesium. This dietary supplement is used to enhance heart function and circulation, which is not the subject of the present invention.
Rath et al.: Joumal of Applied Nutritrion (1996), 48/3, strany 68 - 78 opisujú výživový doplnok obsahujúci arginín, vitamín C a horčík na prevenciu srdcových ochorení a zastavenie progresie koronárnej aterosklerózy, t. j. angíny pectoris, čo taktiež nie je predmetom predloženého vynálezu.Rath et al.: Joumal of Applied Nutritrion (1996), 48/3, pp. 68-78 disclose a nutritional supplement comprising arginine, vitamin C and magnesium for preventing heart disease and arresting the progression of coronary atherosclerosis, i. j. angina pectoris, which is also not an object of the present invention.
Dokument WO 99/51252 opisuje potravinový doplnok, ktorý okrem iného obsahuje arginín, vitamín C a horčík. Tento doplnok sa môže použiť na uľahčenie uvoľnenia hladkého svalstva a vaskulámu diiatáciu. Tento dokument však neopisuje použitie kompozície obsahujúcej arginín, vitamín C a horčíkové zložky na liečenie špecifických ochorení, ktoré sú opísané v predloženom vynáleze.WO 99/51252 discloses a food supplement comprising, inter alia, arginine, vitamin C and magnesium. This supplement can be used to facilitate dilatation of smooth muscle and vascular. However, this document does not disclose the use of a composition comprising arginine, vitamin C and magnesium components for the treatment of the specific diseases described in the present invention.
Dokument WO 01/22958 opisuje kompozíciu obsahujúcu arginín, vitamín C a horčík na liečenie ochorení súvisiacich s aterosklerózou a s nestabilitou plaku, čo taktiež nie je predmetom predloženého vynálezu.WO 01/22958 discloses a composition comprising arginine, vitamin C and magnesium for the treatment of diseases related to atherosclerosis and plaque instability, which is also not an object of the present invention.
Ďalej sa zistilo, že bunková dysfunkcia by mohla byť spôsobená nedostatkom niektorých biochemických látok využívaných ako koenzýmy v cykle trikarboxylových kyselín, v tzv. Krebsovom cykle, v respiračnom cykle a na ďalšie metabolické funkcie buniek hladkého svalstva. Zdravotné problémy, ktorým sa môže potencionálne predchádzať, a ktoré sa môžu liečiť, zahŕňajú nasledujúce orgány a ochorenia:Furthermore, it has been found that cellular dysfunction could be due to a lack of some biochemical agents used as coenzymes in the tricarboxylic acid cycle, the so-called. The Krebs cycle, the respiratory cycle, and other metabolic functions of smooth muscle cells. Health problems that can potentially be prevented and can be treated include the following organs and diseases:
pľúca, oči, uro-genitálny trakt, gastro-intestinálny trakt, tinnitus, impotencia, astma a ďalšie formy obštrukčných ochorení pľúc, glaukóm a ďalšie formy zvýšeného očného tlaku, predmenštruačný syndróm, neplodnosť, spazmus močovodov, močovej rúry, singultácia, žalúdočné kŕče, spazmus žlčovodov.lungs, eyes, urogenital tract, gastro-intestinal tract, tinnitus, impotence, asthma and other forms of obstructive pulmonary disease, glaucoma and other forms of increased eye pressure, premenstrual syndrome, infertility, ureteral spasm, urethra, singularization, gastric spasm bile duct spasm.
Podstata vynálezuSUMMARY OF THE INVENTION
Predmetom tohto vynálezu je podávanie kompozície biochemických látok pacientovi, ktorý trpí spomínanými zdravotným problémami, pričom tieto kompozície pozostávajú aspoň jednej askorbátovej zložky zvolenej zo skupiny zahrnujúcej kyselinu askorbovú, farmaceutický prijateľné soli askorbátu a/alebo ich zmesi, s aspoň jednou arginínovou zložkou zvolenou zo skupiny hydrochloridov arginínu, farmaceutický prijateľných solí arginínu a/alebo ich zmesí, a aspoň jednej horčíkovej zložky zvolenej z horčíka alebo farmaceutický prijateľných solí horčíka a/alebo ich zmesí.It is an object of the present invention to administer a composition of biochemicals to a patient suffering from the aforementioned health problems, which composition comprises at least one ascorbate component selected from the group consisting of ascorbic acid, pharmaceutically acceptable salts of ascorbate and / or mixtures thereof with at least one arginine component selected from the group of hydrochlorides. arginine, pharmaceutically acceptable salts of arginine and / or mixtures thereof, and at least one magnesium component selected from magnesium or pharmaceutically acceptable salts of magnesium and / or mixtures thereof.
Ďalším predmetom tohto vynálezu je podávanie terapeutickej kompozície pacientovi, pozostávajúcej z biochemických látok, ako sú kyselina askorbová, palmitát kyseliny askorbovej, zmesi beta-, gama-, delta-tokoferolu, beta-karotén, biotín, askorbát vápenatý, citrát vápenatý, glycinát vápenatý, zmes karotenoidov: (alfa-karotén, luteín, zea, kryptoxantín), cholekalciferol, glycinát chrómu, citrusové biflavonoidy, koenzým Q10, glycinát medi, kyanokobalamín, d-alfa-tokoferol, d-pantotenát vápenatý, fosfát divápenatý, kyselina folová, inozitol, L-arginín, L-kamitin, L-cysteín, L-lyzín, L-prolín, L-selenometionín, askorbát horečna tý, citrát horečnatý, glycinát horečnatý, chelát mangánu, glycinát molybdénu, niacín, niacínamid, chelát draslíka, pycnogenol, pyridoxín, riboflavín, tiamín, glycinát zinku, nezávisle od dávkovania týchto pridávaných komponentov.Another object of the present invention is to administer a therapeutic composition to a patient comprising biochemical agents such as ascorbic acid, ascorbic acid palmitate, beta-, gamma-, delta-tocopherol, beta-carotene, biotin, calcium ascorbate, calcium citrate, calcium glycinate, carotenoid mixture: (alpha-carotene, lutein, zea, cryptoxanthin), cholecalciferol, chromium glycinate, citrus biflavonoids, coenzyme Q10, copper glycinate, cyanocobalamin, d-alpha-tocopherol, d-pantothenate, dicalcium phosphate, folic acid phosphate, L-arginine, L-carnitine, L-cysteine, L-lysine, L-proline, L-selenomethionine, magnesium ascorbate, magnesium citrate, magnesium glycinate, manganese chelate, molybdenum glycinate, niacin, niacinamide, potassium chelate, pycnogenol, pyridoxine , riboflavin, thiamine, zinc glycinate, independent of the dosage of these added components.
Ďalším predmetom tohto vynálezu je podávanie kompozície biochemických látok, pričom toto zloženie je pacientovi poskytnuté vo forme tabliet, pilúl, injekcií, infúzií, inhalácií, čapíkov alebo ďalších farmaceutický prijateľných nosičov a/alebo prostriedkov na podávanie.It is a further object of the present invention to administer a composition of biochemicals, which composition is provided to the patient in the form of tablets, pills, injections, infusions, inhalations, suppositories or other pharmaceutically acceptable carriers and / or compositions for administration.
Tento koncept bol klinicky testovaný pri niekoľkých už spomínaných zdravotných problémoch, ako sú astma a tinnitus.This concept has been clinically tested for several of the aforementioned health problems, such as asthma and tinnitus.
Liečba takýmito kompozíciami biochemických látok vedie k aspoň čiastočne významnému uvoľneniu buniek hladkého svalstva, k zväčšeniu priemeru arteriol a kapilár (napr. artérií v uchu) vedúcemu k zlepšeniu sluchu, k uvoľneniu buniek hladkého svalstva v pľúcnych bronchiolách a alveolách vedúcemu k zväčšeniu priemeru dýchacích ciest zabezpečujúcemu zmiernenie symptómov astmy, k uvoľneniu kanálikového systému oka vedúcemu k zväčšeniu priemeru napr. slzných kanálikov, čo znižuje očný tlak a následne vedie k zníženiu rizika glaukómu a slepoty, k uvoľneniu buniek hladkého svalstva vajičkovodov a maternice spôsobujúcemu uvoľnenie svalového tkaniva, čo zvyšuje fertilitu a znižuje PMS symptómy, k uvoľneniu buniek hladkého svalstva v žlčovodoch, močovodoch a močovej rúre zväčšujúcemu priemer kanálikov, čo vedie k zníženiu rizika kŕčov spôsobených žlčníkovými alebo obličkovými kameňmi.Treatment with such biochemical compositions results in at least partially significant release of smooth muscle cells, an increase in diameter of arterioles and capillaries (e.g., arteries in the ear) leading to hearing improvement, release of smooth muscle cells in lung bronchioles and alveoli leading to increased diameter relieving asthma symptoms, releasing the duct system of the eye resulting in an increase in diameter e.g. tear ducts, which decreases eye pressure and consequently reduces the risk of glaucoma and blindness, relaxes the oviduct and uterine smooth muscle cells, releasing muscle tissue, increasing fertility and reducing PMS symptoms, releasing smooth muscle cells in the bile ducts, ureters and urinary tract increasing the diameter of the canals, resulting in a reduction in the risk of cramps caused by gallbladder or kidney stones.
Prehľad obrázkov na výkresochBRIEF DESCRIPTION OF THE DRAWINGS
Obr. 1 znázorňuje graf zmeny v objeme pľúc u pacientov trpiacich astmou po podávaní farmaceutickej kompozície podľa vynálezu.Fig. 1 is a graph of lung volume change in asthma patients after administration of the pharmaceutical composition of the invention.
Obr. 2 znázorňuje zlepšenie sluchu u pacientov trpiacich tinnitusom po podávam farmaceutickej kompozície podľa vynálezu.Fig. 2 shows the hearing improvement in patients suffering from tinnitus after administration of the pharmaceutical composition of the invention.
Opísané výhodné riešenia predkladaného vynálezu a nasledujúce príklady predstavujú iba názorné príklady.The preferred embodiments of the present invention described and the following examples are illustrative only.
Príklady uskutočnenia vynálezuDETAILED DESCRIPTION OF THE INVENTION
Kompozície biochemických látok, ktoré sú uvedené v nasledujúcej tabuľke, sa podávali pacientom v denných dávkach v jednotkách, ktoré sú uvedené v tomto príklade.The biochemical compositions shown in the following table were administered to patients in daily doses in the units indicated in this example.
mg = miligram mcg = mikrogrammg = milligram mcg = microgram
I.U. = medzinárodné jednotky (Intemational Units)I.U. = Intemational Units
Kompozícia biochemických látok podľa tohto príkladu však môže v jednotlivých komponentoch varírovať, odlišovať sa od použitého zloženia, a nezávisí od ich množstva, ktoré je na viac než 80 % zhodné s takýmito látkami. Okrem toho nemôže byť množstvo jednotlivých zložiek poskytovaných denne menej ako 10 % a nie viac ako 1000 % množstva uvedeného v príklade.However, the biochemical composition of this example may vary in the individual components, may differ from the composition used, and does not depend on an amount that is more than 80% identical to such substances. In addition, the amount of individual components provided per day may not be less than 10% and not more than 1000% of the amount given in the example.
Koncept tohto vynálezu bol testovaný vo výhľadových klinických štúdiách u ôsmich pacientov trpiacich astmou. Títo pacienti dostávali uvedené biochemické látky ako dennú dávku počas štyroch mesiacov. Na začiatku a na konci štúdie sa každému pacientovi zmeral objem pľúc. Počas štúdie sa u týchto pacientov trpiacich astmou zvýšil objem pľúc v priemere o viac ako 20 %. Najviac signifikantným výsledkom tejto štúdie bol fakt, že percento zvýšenia objemu pľúc bolo oveľa vyššie u pacientov s najnižšími východiskovými objemami, čo indikuje, že táto terapia je účinná hlavne u pacientov s pokročilou astmou a pokročilými poruchami dýchania, ako znázorňuje graf na obr. 1.The concept of the invention has been tested in prospective clinical trials in eight patients suffering from asthma. These patients received these biochemical agents as a daily dose for four months. At the start and end of the study, each patient's lung volume was measured. During the study, lung volume increased by more than 20% on average in these asthma patients. The most significant outcome of this study was that the percentage of lung volume increase was much higher in patients with the lowest baseline volumes, indicating that this therapy is particularly effective in patients with advanced asthma and advanced respiratory disorders, as shown in the graph in FIG. First
Koncept tohto vynálezu sa testoval vo výhľadových klinických štúdiách u 18 pacientov trpiacich tinnitusom počas štyroch mesiacov. Kvalita sluchu bola objektívne stanovená audiometriou. Počiatočné a konečné výsledky audiometrických meraní sú uvedené na grafe na obr. 2.The concept of this invention was tested in prospective clinical trials in 18 patients suffering from tinnitus for four months. Hearing quality was objectively determined by audiometry. The initial and final results of the audiometric measurements are shown in the graph of FIG. Second
Päť pacientov nemalo žiadne alebo iba malé zlepšenie sluchu (0-10 decibelov [dB]), pri ôsmich pacientoch sa sluch zlepšil o 10 až 20 dB, pri dvoch o 20 až 30 dB, pri dvoch o 30 až 40 dB a pri jednom pacientovi sa zaznamenalo zlepšenie sluchu o 40 až 50 dB.Five patients had no or little hearing improvement (0-10 decibels [dB]), eight patients had hearing improvement by 10 to 20 dB, two by 20 to 30 dB, two by 30 to 40 dB, and one patient a hearing improvement of 40 to 50 dB was noted.
Je zrejmé, že podávanie kompozícii pacientom, ktorých ohrozujú alebo ktorí sú postihnutí zdravotnými ťažkosťami aspoň čiastočne spôsobenými konstrikciou buniek hladkého svalstva v ich telesných orgánoch, je výhodné.Obviously, administration of the compositions to patients who are at risk of or affected by health problems at least in part due to the constriction of smooth muscle cells in their body organs is preferred.
Claims (6)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00112811A EP1163904B1 (en) | 2000-06-16 | 2000-06-16 | Composition for the prevention of smooth muscle diseases comprising ascorbate, arginine and magnesium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK8232001A3 SK8232001A3 (en) | 2002-01-07 |
| SK285454B6 true SK285454B6 (en) | 2007-01-04 |
Family
ID=8168995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK823-2001A SK285454B6 (en) | 2000-06-16 | 2001-06-13 | Use of biochemical substances in a composition for the prevention and treatment of health conditions caused by constrictions of smooth muscle cells in organs of the human body |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1163904B1 (en) |
| JP (1) | JP2002047183A (en) |
| KR (1) | KR100793573B1 (en) |
| CN (1) | CN1245973C (en) |
| AT (1) | ATE323479T1 (en) |
| AU (1) | AU780906C (en) |
| BR (1) | BR0103256A (en) |
| CA (1) | CA2350713C (en) |
| CZ (1) | CZ20012178A3 (en) |
| DE (1) | DE60027415T2 (en) |
| DK (1) | DK1163904T3 (en) |
| ES (1) | ES2258426T3 (en) |
| HK (1) | HK1043947A1 (en) |
| HU (1) | HUP0102489A2 (en) |
| IL (1) | IL143697A (en) |
| NO (1) | NO20013004L (en) |
| PL (1) | PL348097A1 (en) |
| PT (1) | PT1163904E (en) |
| RU (1) | RU2280441C2 (en) |
| SK (1) | SK285454B6 (en) |
| TR (1) | TR200101673A2 (en) |
| UA (1) | UA77147C2 (en) |
| ZA (1) | ZA200104931B (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2258426T3 (en) * | 2000-06-16 | 2006-09-01 | Matthias Dr. Med. Rath | COMPOSITION FOR THE PREVENTION OF DISEASES OF SMOOTH MUSCLES THAT INCLUDE ASCORBATE, ARGININE AND MAGNESIUM. |
| US6576634B1 (en) * | 2000-07-07 | 2003-06-10 | N.V. Nutricia | Pharmaceutical or dietetic preparation for improvement of fertility and sperm quality |
| US6372264B1 (en) * | 2000-08-24 | 2002-04-16 | Gusty Winds Corporation | Method of reducing calcified arterial plaque buildup and cellular malfunction and for balancing ionic calcium |
| CA2422819C (en) * | 2000-09-22 | 2008-07-08 | Mars Uk Limited | Food supplement |
| UA77660C2 (en) | 2000-10-03 | 2007-01-15 | Compositions and methods for reducing plasma lipoprotein a level in human | |
| AU2003239154B2 (en) * | 2002-01-31 | 2007-02-01 | Chemstop Pty Ltd | Process for the preparation of a nutrient formulation |
| AUPS019802A0 (en) * | 2002-01-31 | 2002-02-21 | Chemstop Pty Ltd | Nutrient formulation |
| GB0202900D0 (en) | 2002-02-07 | 2002-03-27 | Laxdale Ltd | Novel formulations of drugs |
| US20050238693A1 (en) * | 2002-05-20 | 2005-10-27 | Chemstop Pty Ltd. | Process for the preparation and activation of susbstances and a means of producing same |
| WO2004017955A1 (en) * | 2002-08-22 | 2004-03-04 | Vasopharm Biotech Gmbh | L-arginine containing pharmaceutical composition |
| US9655966B2 (en) * | 2002-08-28 | 2017-05-23 | Kedar N. Prasad | Micronutrient formulations for radiation applications |
| WO2004069822A1 (en) * | 2003-02-05 | 2004-08-19 | Santen Pharmaceutical Co., Ltd. | Composition for inhibiting steroid side effect |
| JP4723476B2 (en) * | 2003-02-14 | 2011-07-13 | チルドレンズ ホスピタル アンド リサーチ センター アット オークランド | Treatment of conditions associated with reduced nitric oxide bioavailability, including elevated arginase status |
| MXPA05012859A (en) * | 2003-05-30 | 2006-02-22 | Matthias Rath | Nutritional composition and method of inhibiting smooth muscle cell contraction thereof. |
| BRPI0509372A (en) * | 2004-03-30 | 2007-09-11 | Unilever Nv | composition, skin lightening product, methods of inhibiting melanin production, increasing the ratio of light melanin to dark melanin in the skin of a mammal, and inhibiting the transport of melanin from melanocytes to an individual's skin. keratinocytes, and use of a composition |
| FR2884691B1 (en) * | 2005-04-21 | 2007-07-20 | Formquest Ltd | FOOD SUPPLEMENT COMPRISING A COMBINATION OF ANTIOXIDANT AGENTS AND ENERGY AGENTS USEFUL AS AID FOR FERTILITY IN MAN AND IN WOMEN |
| FR2884692B1 (en) * | 2005-04-21 | 2009-08-14 | Formquest Ltd | FOOD SUPPLEMENT COMPRISING AN ASSOCIATION OF ANTIOXIDANT AGENTS AND CARNITINE, OBTAINED BY ENDOGENEOUS OR EXOGENOUS SYNTHESIS, AS AID FOR FERTILITY IN MAN AND WOMEN |
| US7754700B2 (en) | 2006-04-24 | 2010-07-13 | Trager Seymour F | Composition and methods for alleviating symptoms of neurotoxicity |
| EP2253307B1 (en) * | 2006-05-12 | 2015-07-08 | Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG | L-Carnitin for supression of crystallisation |
| EP1862163A1 (en) | 2006-05-12 | 2007-12-05 | Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG | L-Carnitin for supression of crystallisation |
| RU2315612C1 (en) * | 2006-08-29 | 2008-01-27 | Открытое Акционерное Общество Завод Экологической Техники И Экопитания "Диод" | Agent for treatment of eye disease |
| WO2011033884A1 (en) * | 2009-09-18 | 2011-03-24 | 明治乳業株式会社 | Prophylactic agent for muscular contracture |
| AT510810B1 (en) * | 2010-12-09 | 2017-09-15 | Gonadosan Gmbh | COMBINATION PROCEDURE FOR IMPROVING FEMALE FERTILITY |
| JP2013049670A (en) * | 2011-08-04 | 2013-03-14 | Fancl Corp | Ascorbic acid preparation |
| EA201790017A1 (en) * | 2014-06-24 | 2017-06-30 | Дедраф Холдинг Б.В. | NEW MINERAL COMPOSITION |
| CN104688774A (en) * | 2015-02-17 | 2015-06-10 | 胡梨芳 | Lysine and calcium hydrophosphate pharmaceutical composition comprising chiral isomeric compound and application of pharmaceutical composition |
| CN105687204B (en) * | 2016-04-15 | 2018-05-25 | 石家庄东华金龙化工有限公司 | A kind of glycine metal chelate complex and preparation method thereof |
| CN106213522A (en) * | 2016-08-05 | 2016-12-14 | 郑家福 | Nutrient and healthcare products |
| CN108685754A (en) * | 2018-07-30 | 2018-10-23 | 郑州兰茜生物工程有限公司 | A kind of auristilla for the ear function that relaxes for tinnitus and with strong ear |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5535049A (en) * | 1978-09-04 | 1980-03-11 | Otsuka Pharmaceut Factory Inc | Amino acid transfusion for cancerous patient |
| US5650418A (en) * | 1990-06-04 | 1997-07-22 | Therapy 2000 | Therapeutic lysine salt composition and method of use |
| US5278189A (en) * | 1990-06-04 | 1994-01-11 | Rath Matthias W | Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A) |
| US5198465A (en) * | 1991-06-19 | 1993-03-30 | Dioguardi Francesco S | Compositions based on amino acids for preventing and treating precursor deficiencies in the synthesis of collagen |
| GB2268871A (en) * | 1992-07-04 | 1994-01-26 | Bio Nutritional Health Service | Composition for use as a food or food supplement |
| US5891459A (en) * | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
| US5626883A (en) * | 1994-04-15 | 1997-05-06 | Metagenics, Inc. | Ascorbic acid compositions providing enhanced human immune system activity |
| EP0891771A1 (en) * | 1997-07-08 | 1999-01-20 | Health Now, Inc. | Compositions comprising lysine and ascorbate compounds for the treatment and prevention of cardiovascular diseases |
| AU3221599A (en) * | 1998-04-03 | 1999-10-25 | Daily Wellness Company, The | Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation |
| GB9922751D0 (en) * | 1999-09-27 | 1999-11-24 | Kenton Corp Limited | A pharmaceutical composition for stabilising atherosclerotic plaques |
| ES2258426T3 (en) * | 2000-06-16 | 2006-09-01 | Matthias Dr. Med. Rath | COMPOSITION FOR THE PREVENTION OF DISEASES OF SMOOTH MUSCLES THAT INCLUDE ASCORBATE, ARGININE AND MAGNESIUM. |
-
2000
- 2000-06-16 ES ES00112811T patent/ES2258426T3/en not_active Expired - Lifetime
- 2000-06-16 DK DK00112811T patent/DK1163904T3/en active
- 2000-06-16 AT AT00112811T patent/ATE323479T1/en not_active IP Right Cessation
- 2000-06-16 EP EP00112811A patent/EP1163904B1/en not_active Expired - Lifetime
- 2000-06-16 PT PT00112811T patent/PT1163904E/en unknown
- 2000-06-16 DE DE60027415T patent/DE60027415T2/en not_active Expired - Fee Related
-
2001
- 2001-06-12 IL IL143697A patent/IL143697A/en not_active IP Right Cessation
- 2001-06-13 SK SK823-2001A patent/SK285454B6/en unknown
- 2001-06-13 BR BR0103256-9A patent/BR0103256A/en not_active Application Discontinuation
- 2001-06-15 JP JP2001181658A patent/JP2002047183A/en not_active Ceased
- 2001-06-15 PL PL01348097A patent/PL348097A1/en unknown
- 2001-06-15 RU RU2001116855/15A patent/RU2280441C2/en not_active IP Right Cessation
- 2001-06-15 CA CA002350713A patent/CA2350713C/en not_active Expired - Fee Related
- 2001-06-15 TR TR2001/01673A patent/TR200101673A2/en unknown
- 2001-06-15 AU AU51942/01A patent/AU780906C/en not_active Ceased
- 2001-06-15 KR KR1020010033746A patent/KR100793573B1/en not_active IP Right Cessation
- 2001-06-15 UA UA2001064163A patent/UA77147C2/en unknown
- 2001-06-15 ZA ZA200104931A patent/ZA200104931B/en unknown
- 2001-06-15 HU HU0102489A patent/HUP0102489A2/en unknown
- 2001-06-15 CZ CZ20012178A patent/CZ20012178A3/en unknown
- 2001-06-15 CN CNB011243309A patent/CN1245973C/en not_active Expired - Fee Related
- 2001-06-15 NO NO20013004A patent/NO20013004L/en not_active Application Discontinuation
-
2002
- 2002-07-30 HK HK02105586A patent/HK1043947A1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1163904B1 (en) | 2006-04-19 |
| KR20010113499A (en) | 2001-12-28 |
| ATE323479T1 (en) | 2006-05-15 |
| AU5194201A (en) | 2001-12-20 |
| ZA200104931B (en) | 2001-12-20 |
| DE60027415T2 (en) | 2006-10-19 |
| DK1163904T3 (en) | 2006-08-14 |
| CA2350713C (en) | 2007-01-16 |
| CZ20012178A3 (en) | 2002-04-17 |
| HK1043947A1 (en) | 2002-10-04 |
| JP2002047183A (en) | 2002-02-12 |
| HUP0102489A2 (en) | 2003-11-28 |
| BR0103256A (en) | 2002-03-12 |
| AU780906C (en) | 2006-04-27 |
| DE60027415D1 (en) | 2006-05-24 |
| ES2258426T3 (en) | 2006-09-01 |
| RU2280441C2 (en) | 2006-07-27 |
| IL143697A (en) | 2006-12-10 |
| SK8232001A3 (en) | 2002-01-07 |
| CA2350713A1 (en) | 2001-12-16 |
| UA77147C2 (en) | 2006-11-15 |
| NO20013004D0 (en) | 2001-06-15 |
| CN1245973C (en) | 2006-03-22 |
| IL143697A0 (en) | 2002-04-21 |
| EP1163904A1 (en) | 2001-12-19 |
| KR100793573B1 (en) | 2008-01-14 |
| NO20013004L (en) | 2001-12-17 |
| PT1163904E (en) | 2006-07-31 |
| AU780906B2 (en) | 2005-04-21 |
| TR200101673A2 (en) | 2002-02-21 |
| PL348097A1 (en) | 2001-12-17 |
| CN1333020A (en) | 2002-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK285454B6 (en) | Use of biochemical substances in a composition for the prevention and treatment of health conditions caused by constrictions of smooth muscle cells in organs of the human body | |
| US6686340B2 (en) | Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells | |
| RU2289406C2 (en) | METHODS AND COMPOSITION FOR DECREASING LIPOPROTEIN (a) CONTENT IN PLASMA AND REDUCING FACTORS FOR RISK OF CARDIOVASCULAR DISEASES | |
| US6207190B1 (en) | Dosage forms for the treatment of the chronic glaucomas | |
| US11628186B2 (en) | Method and composition for the reduction of viral replication, duration and spread of the COVID-19 and the flu | |
| US20060088603A1 (en) | Compositions and methods for nutrition supplementation | |
| US20080268066A1 (en) | Synergistic Formulation for Preventing and/or Treating Diabetes | |
| US20070082064A1 (en) | Nutritional or dietary supplement for the treatment of macular degeneration | |
| US9420819B2 (en) | Nutritional formulation | |
| US20210346327A1 (en) | Method for enhancing energy production and metabolism in cells | |
| PT1060959E (en) | Guide loop height-adjusting device for a vehicle seat belt | |
| GB2600668A (en) | Alpha Lipoic Acid (A-ALA) and Alpha Lipoic Acid (R-ALA) As a Pharmaceutical Product for Intravenous Application to reduce Inflammation from infection. | |
| MXPA05004465A (en) | Use of propionyl l-carnitine for the preparation of a medicament for the treatment of glaucoma. | |
| US20220160652A1 (en) | Use of vitamin k in combination with anticoagulants | |
| WO2022232693A1 (en) | Ketamine and cannabis for the treatment of emotional disorders | |
| CN115590912A (en) | Application of composition in preparation of medicine for improving ischemic stroke sequelae | |
| Ulbricht | High blood pressure: An integrative approach: A natural standard monograph | |
| Kutyrina | Treatment of arterial hypertension in chronic kidney diseases |